HTG Molecular Diagnostics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-06-08: Form 8-K; Period of report 2023-06-06; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2023-06-05: Form 8-K; Period of report 2023-06-01; Description 1.03 Bankruptcy or Receivership; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 1.03.
- 2023-05-24: Form 8-K; Period of report 2023-05-18; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2023-05-16: Form 8-K; Period of report 2023-05-16; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-06-08 | 8-K | 2023-06-06 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 6, 2023, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the Company's filing for protection under Chapter 11 of the U.S. Bankruptcy Code (the "Filing") and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock (the “Securities”) will be delisted from Nasdaq. | htgm-20230606.htm |
| 2023-06-05 | 8-K | 2023-06-01 | 1.03 Bankruptcy or Receivership; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.03 On June 5, 2023 (the “Petition Date”), HTG Molecular Diagnostics, Inc. (the “Company”) filed a voluntary petition (Case No. 23-10732) for relief under Chapter 11 of the United States Bankruptcy Code (the “Code”) in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such case, the “Case”). 2.04 The filing of the Case constituted an event of default that accelerated all of the Company’s obligations under the Company’s Loan and Security Agreement, dated June 24, 2020, as amended, with Silicon Valley Bank, N.A., a division of First-Citizens Bank and Trust Company (“Loan Agreement”), comprising an outstanding principal amount of $2,687,255, together with accrued interest and all applicable fees and other financial obligations. 5.02 On June 1, 2023, the Company notified Byron T. Lawson, Senior Vice President and Chief Commercial Officer of the Company, of his termination of employment, effective June 2, 2023. | htgm-20230601.htm |
| 2023-05-24 | 8-K | 2023-05-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On May 18, 2023, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”). | htgm-20230518.htm |
| 2023-05-16 | 8-K | 2023-05-16 | 8.01 Other Events | 8.01 HTG Molecular Diagnostics, Inc. (the “Company” or “HTG”) is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. | htgm-20230516.htm |
| 2023-05-10 | 8-K | 2023-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2023, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results as of and for the quarter ended March 31, 2023. | htgm-20230510.htm |
| 2023-04-25 | 8-K | 2023-04-25 | 8.01 Other Events | 8.01 HTG Molecular Diagnostics, Inc. (the “Company” or “HTG”) has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. | htgm-20230425.htm |
| 2023-02-03 | 8-K | 2023-02-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Our named executive officers are eligible to receive annual performance-based bonuses pursuant to their letter agreements with us. | htgm-20230202.htm |
| 2023-01-06 | 8-K | 2023-01-06 | 2.02 Results of Operations and Financial Condition | 2.02 On January 6, 2023, HTG Molecular Diagnostics, Inc. issued a press release announcing certain preliminary financial results as of and for the year ended December 31, 2022. | htgm-20230106.htm |